Medilink has developed ADC-related technologies with independent intellectual property rights, where the indications have covered the top 10 tumor fields in terms of morbidity and mortality.
The following table summarizes the development status of our drug candidates and each drug candidate as of the latest practicable date:
Project
Target
Indications
Platform
Discovery
Pre -Clinical
IND
Phase 1
Phase 2
Phase 3
BLA
-
Solid Tumor
YL202
-
Solid Tumor
Project 3
-
Solid Tumor
Project 4
-
Solid Tumor
Project 5
-
Solid Tumor
Project 6
-
Solid Tumor
Project 7
-
Solid Tumor
